Sign up
Pharma Capital

Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions

Paul Rennie talked timeline to clinical trial results with investors.
Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions
Paul Rennie, chief executive officer, Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals (ASX:PAR) chief executive officer, Paul Rennie, joined Proactive's CEO Sessions in Melbourne on Tuesday 16th May and Sydney on Wednesday 17th May.

Paradigm has results from its Phase 2 hay fever trial pending in six weeks.

ACCESS THE FULL PRESENTATION HERE

View full PAR profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.